Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NeutroCure

Financiado

Cerrado

Development of smart amplifiers of reactive oxygen species specific to aberran...

Development of smart amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases cancer and myeloablation. Reactive oxygen species (ROS) have key functions in healthy organism such as redox signaling for regulation of cell growth, triggering formation of neutrophil extracellular traps (NETs), and modulation of inflammation. Since in hi... ver más

31/12/2024

FAU

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

FRIEDRICHALEXANDERUNIVERSITAET ERLANGENNUERNB... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 13 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-12-31

FETOPEN-01-2018-2019-2020: FET-Open Challenging Current Thinki...

I+D

Cerrada hace 6 años

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

13 Participantes

FAU

629.00K€ | Lider

RPK SOCIEDAD COOPERATIVA

1.04M€ | Participante

SURREY

N.D. | Participante

PRONOXIS AB

N.D. | Participante

Proyectos interesantes

ROS IN INFLAMMATION

Medical Technol...

Data Science

178K€ Cerrado

REDOXIT

Medical Technol...

Data Science

144K€ Cerrado

SAF2015-71304-REDT

Medical Technol...

Data Science

35K€ Cerrado

PID2019-108651RJ-I00

Medical Technol...

Data Science

182K€ Cerrado

PCIN-2017-093

Medical Technol...

Data Science

121K€ Cerrado

MOLINFLAM

Medical Technol...

Applied Physics

1M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 64 meses Fecha Inicio: 2019-08-30
Fecha Fin: 2024-12-31

Líder del proyecto

FRIEDRICHALEXANDERUNIVERSITAET ERLANGENNUERNB... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Reactive oxygen species (ROS) have key functions in healthy organism such as redox signaling for regulation of cell growth, triggering formation of neutrophil extracellular traps (NETs), and modulation of inflammation. Since in high concentration ROS are damaging to tissues, nature has evolved precise mechanisms to control their generation at the required time, concentration and space, proximal to their target. Disturbance of these mechanisms leads to aberrant ROS production that causes uncontrolled inflammation, occurs in myeloablation caused by radio- or chemotherapy and is a crucial feature of cancer cell phenotype as well as autoimmunity. Despite the damaging properties of ROS it is a paradox that pharmaceutical ROS amplifiers can reverse (cure) many pathologic features. For example, ROS-induced cancer cell killing inhibits cancer growth, ROS-induced deactivation of T-cells and NETs generation contributes to resolution of inflammation, and ROS-induced boosting of haematopoiesis can relieve myeloablation. These exciting possibilities have not been realized in clinical settings yet, since the high level of temporal and spatial control of ROS generation, required to allow for safe patient treatment, has yet not been achieved for any known drug. NeutroCure will be the first attempt to achieve a breakthrough solution to this problem. Using an innovative approach based on the multiple-trigger prodrug activation, this consortium will develop safe ROS amplifiers capable of boosting ROS specifically in abnormal polymorphonuclear neutrophils associated with cancer, uncontrolled inflammation and relevant for myeloablation without affecting normal cells. NeutroCure consists of 6 European academic partners and an SME who will promote commercialization of the new drugs. We expect that this project will have a great positive impact on the Society by providing previously unexplored treatment solutions for severe pathological conditions caused by dysregulated ROS-production.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores